The Muscular Dystrophy Association (MDA), an organisation committed to transforming the lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases, is celebrating the decision by the US Food and Drug Administration (FDA) to offer accelerated marketing approval to casimersen (Amondys 45) intended for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 45, it was reported on Thursday.
The product is the fourth exon-skipping, disease-modifying drug to treat DMD. It will be offered in the US and marketed by Sarepta Therapeutics.
This development highlights the importance of years of commitment to supporting and funding breakthrough research by the MDA and others into gene identification and unlocking the cause of DMD.
The US FDA's decision to grant accelerated approval to Amondys 45 was based on positive results from a global, randomised, double-blind, placebo-controlled phase three clinical trial (ESSENCE) that is assessing the efficacy and safety of the drug in patients with DMD amenable to skipping exon 45. The current approval is based on findings that AMONDYS 45 has met the full statutory standards for safety and effectiveness and demonstrated an increase in dystrophin production in skeletal muscle of patients amenable to exon 45 skipping. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT